Polish Registry of Takotsubo Syndrome

Takotsubo Syndrome Clinical Trial

— Pol-Tako  

Official title:

Polish Registry of Takotsubo Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04634487
• Other study ID #: Pol-Tako
• Status: Recruiting
• Start date: October 1, 2020
• Est. completion date: January 2030

Study information

• Verified date: November 2020
• Source: Medical University of Warsaw
• Contact: Monika Budnik, PhD
• Phone: +48225991958
• Email: mbudnik[@]wum.edu.pl
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Polish registry of takotsubo syndrome

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: January 2030
• Est. primary completion date: October 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

all patients with takotsubo syndrome

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Syndrome
• Takotsubo Cardiomyopathy
• Takotsubo Syndrome

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
Poland	Medical University of Warsaw	Warsaw

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Warsaw

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with in-hospital complications and mortality	In hospital complications include atrial fibrillation, ventricular tachycardia, ventricular fibrillation, atrioventricular block, cardiogenic shock, cardiac arrest	through study completion, an average of 1 year
Secondary	Number of participants with complications with echocardiography	Complications include: severe mitral regurgitation, fluid in the pericardium, right ventricle disfunction, ventricular septum rupture	through study completion, an average of 1 year